Individuals with obesity, CKD and T2DM were frequently prescribed RAAS blockade, statins, insulin and sulphonylureas, but infrequently prescribed diabetes therapy with weight‐lowering effects, including GLP1RAs and SGLT2is. This evidence concerns the gene INS and type 2 diabetes mellitus.